B‐cell activating factor receptor expression in B‐lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70708 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Parastou Tizro und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, City of Hope Comprehensive Cancer Center, Duarte, California, USA. Hauptthemen laut MEDLINE: B-Cell Activation Factor Receptor, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Cluster of differrentiation 19 (CD19)‐directed therapies have significantly improved outcomes in B‐cell malignancies; however, relapse driven by antigen escape remains a major clinical challenge, underscoring the need for alternative therapeutic targets. The B‐cell activating factor receptor (BAFF‐R), a key regulator of B‐cell survival, is highly expressed in mature B‐cell neoplasms, but its relevance in B‐lymphoblastic leukaemia (B‐ALL) remains unclear. We assessed BAFF‐R expression in diagnostic and relapsed fresh B‐ALL samples using multi‐parameter flow cytometry. BAFF‐R was consistently expressed in most cases, albeit at lower levels than in mature B cells, and expression was retained in the majority of CD19‐negative relapses following CD19‐directed therapy. Notably, tumor protein p53 ( TP53 ) alterations were significantly enriched in CD19‐negative immune escape disease (68.8% vs. 21.7%; p = 0.0006; OR = 7.9), yet BAFF‐R expression remained preserved in this high‐risk group. These findings establish BAFF‐R as a stable immunotherapeutic target in B‐ALL, including in CD19‐negative and TP53 ‐altered relapsed disease, and underscore its relevance amid ongoing early‐phase clinical trials of BAFF‐R–directed chimeric antigen receptor (CAR) T‐cell therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Toni Stephenson Lymphoma Center, Beckman Research Institute, City of Hope, Duarte, California, USA.
- Department of Computational and Quantitative Medicine, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
ORCID-Profile: Parastou Tizro, Ibrahim Aldoss, Xiuli Wang, Michael Palmer, Soungchul Cha, Huiyan Ma, Vinod Pullarkat, Elizabeth Budde, Guido Marcucci, Winston Lee, Joo Y Song
Zitieren
APA
Tizro, P., Aldoss, I., Wang, X., Kwak, L. W., Dong, Z., Arango, K., Palmer, M., Cha, S., Hughes, J., Ma, H., Pullarkat, V., Budde, E., Marcucci, G., Lee, W., Soma, L., Forman, S., & Song, J. Y. (2026). B‐cell activating factor receptor expression in B‐lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy. British Journal of Haematology. https://doi.org/10.1111/bjh.70708
Vancouver
Tizro P, Aldoss I, Wang X, Kwak LW, Dong Z, Arango K, et al. B‐cell activating factor receptor expression in B‐lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy. British Journal of Haematology. 2026. doi:10.1111/bjh.70708
BibTeX
@article{Tizro2026,
author = {Tizro, Parastou and Aldoss, Ibrahim and Wang, Xiuli and Kwak, Larry W and Dong, Zhenyuan and Arango, Kevin and Palmer, Michael and Cha, Soungchul and Hughes, Jessica and Ma, Huiyan and Pullarkat, Vinod and Budde, Elizabeth and Marcucci, Guido and Lee, Winston and Soma, Lorinda and Forman, Stephen and Song, Joo Y},
title = {B‐cell activating factor receptor expression in B‐lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70708}
}
EUVIMED